Literature DB >> 3541824

Lipid-soluble and water-soluble beta-blockers. Comparison of the central nervous system depressant effect.

F M Gengo, L Huntoon, W B McHugh.   

Abstract

The sedative effects of a relatively lipid-soluble and a water-soluble beta-blocker were compared in 20 male hypertensives, 30 to 60 years old. In a blinded, randomized, crossover study, critical flash fusion frequency and computerized Stroop Word Test were used to assess psychomotor function parameters during a drug-free control day and then following 14 days of either metoprolol, 150 mg daily, or atenolol, 100 mg daily, treatment. Both drugs caused subtle but significant reductions in both parameters of sedation (critical flash fusion frequency and computerized Stroop Word Testing). Sedation was significantly related to serum concentrations of both drugs. The maximum drug-induced change was 17.2% +/- 9% for metoprolol and 19.6% +/- 3% for atenolol. The duration of effect was six hours after atenolol and two hours after metoprolol. Blood pressure control for all patients was similar during both treatment phases. These results demonstrate that relative lipid solubility does not reliably predict the neurologic effects of beta-blockers. The intensity of drug-induced sedation was similar, but the water-soluble agent produced a longer duration of sedative activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3541824     DOI: 10.1001/archinte.147.1.39

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  12 in total

1.  Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol.

Authors:  E S Dimenäs; C G Dahlöf; B Heibel; R G Moore; B K Olofsson; G E Westergren; P W Lücker
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway.

Authors:  A N Nicholson; N A Wright; M B Zetlein; D Currie; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

Review 3.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

5.  Cognitive function in hypertensives treated with atenolol or propranolol.

Authors:  D M Palac; R D Cornish; W J McDonald; D A Middaugh; D Howieson; S P Bagby
Journal:  J Gen Intern Med       Date:  1990 Jul-Aug       Impact factor: 5.128

6.  Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy.

Authors:  C Dahlöf; E Dimenäs; B Olofsson
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

Review 7.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

8.  Nonlinear distribution of atenolol between plasma and cerebrospinal fluid.

Authors:  F M Gengo; S C Fagan; L N Hopkins; D Wagner; D P Schuster
Journal:  Pharm Res       Date:  1989-03       Impact factor: 4.200

9.  The effects of captopril vs atenolol on memory, information processing and mood: a double-blind crossover study.

Authors:  I J Deary; S Capewell; C Hajducka; A L Muir
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

Review 10.  The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.

Authors:  S Nattel; G Gagne; M Pineau
Journal:  Clin Pharmacokinet       Date:  1987-11       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.